Adenoid cystic carcinoma
Clinical trials for Adenoid cystic carcinoma explained in plain language.
Never miss a new study
Get alerted when new Adenoid cystic carcinoma trials appear
Sign up with your email to follow new studies for Adenoid cystic carcinoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill takes on rare salivary gland and colon cancers
Disease control OngoingThis early-stage trial is testing an experimental oral drug called RGT-61159 in about 105 people with two types of cancer that have come back or stopped responding to treatment: adenoid cystic carcinoma (a rare salivary gland cancer) and colorectal cancer. The main goals are to c…
Matched conditions: ADENOID CYSTIC CARCINOMA
Phase 1 • Sponsor: Rgenta Therapeutics Inc • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New antibody aims to preserve immune checkpoint while fighting cancer
Disease control OngoingResearchers are testing an experimental antibody called ONC-392 in people with advanced solid tumors, including non-small cell lung cancer and melanoma. The trial gives ONC-392 alone or with pembrolizumab, an approved immunotherapy, to see what doses are safe and how the body pro…
Matched conditions: ADENOID CYSTIC CARCINOMA
Phase 1/2 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New liposomal drug shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-stage study tests a new drug called E7389 liposomal formulation in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. The study also looks at how the drug works in speci…
Matched conditions: ADENOID CYSTIC CARCINOMA
Phase 1 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a new drug combo shrink Hard-to-Treat salivary gland tumors?
Disease control OngoingThis phase 2 trial is testing whether an experimental drug called 9-ING-41, when combined with the chemotherapy drug carboplatin, can help people with advanced or metastatic salivary gland cancer. The study aims to see if the combination can shrink tumors or slow their growth. Pa…
Matched conditions: ADENOID CYSTIC CARCINOMA
Phase 2 • Sponsor: Glenn J. Hanna • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Immunotherapy duo takes on rare tumors
Disease control OngoingThis phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…
Matched conditions: ADENOID CYSTIC CARCINOMA
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shows promise for rare salivary gland cancer
Disease control OngoingThis study tests a combination of two drugs—pemetrexed (chemotherapy) and pembrolizumab (immunotherapy)—in people with salivary gland cancer that has returned or spread. The goal is to see if this combo can shrink tumors or slow the disease. About 45 adults with advanced salivary…
Matched conditions: ADENOID CYSTIC CARCINOMA
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug shows promise against rare salivary gland cancer
Disease control OngoingThis study tests the drug lenvatinib in 33 people with advanced adenoid cystic carcinoma that has returned or spread. Lenvatinib is a daily pill that blocks cancer cell growth and cuts off blood supply to tumors. The main goal is to see if the drug can shrink tumors by at least 2…
Matched conditions: ADENOID CYSTIC CARCINOMA
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug combo shows promise for rare salivary gland cancers
Disease control OngoingThis study tests whether two drugs, lenvatinib and pembrolizumab, can shrink or slow the growth of advanced salivary gland cancers, including adenoid cystic carcinoma, that have come back or spread. About 64 participants will receive the combination therapy. The goal is to see ho…
Matched conditions: ADENOID CYSTIC CARCINOMA
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC